Duocarmycin ADCs for use in treatment of endometrial cancer
AssigneesSynthon Biopharmaceuticals B.V., Yale University
InventorsAlessandro Davide Santin, Peter Johannes Goedings
Life of this patent
Estimating the term…
Abstract
The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors expressing HER2, wherein the human solid tumor expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2− or 1+ and HER2 FISH negative tumor tissue status.
Claims23
A method of treating endometrial cancer expressing HER2 in a human patient, comprising administering to said patient a therapeutically effective amount of a compound of formula (I)
- wherein
- anti-HER2 Ab is an anti-HER2 antibody or an anti-HER2 antibody fragment able to bind HER2,
- n is 0, 1, 2, or 3,
- m represents an average DAR of from 1 to 4,
- R1 is selected from the group consisting of
- y is 1-16, and
- R2 is selected from the group consisting of
A method of treating endometrial cancer expressing HER2 in a human patient, comprising administering to said patient a therapeutically effective amount of a compound having the structure
- wherein 2.5-2.9 represents an average DAR for the compound.
Dependencies are inferred from the claim text.